Literature DB >> 19663611

Inhalative iloprost - pharmacology and clinical application.

Ralf Ewert1, Christoph Schäper, Michael Halank, Sven Gläser, Christian F Opitz.   

Abstract

Iloprost, as a stable analog of endogenous prostacyclin, has far-reaching pharmacological effects. For several years already it has been used successfully in its intravenous and inhalative forms for treating patients with pulmonary hypertension (PH). Since the development of efficient nebulizers that guarantee a constant output of the effective agent, inhalative iloprost has become an important alternative in the drug treatment of PH. Inhalative iloprost is an effective and safe partner for other classes of substances in combination therapy, which is becoming ever more frequently necessary. In addition, it is also used in the acute testing of pulmonary vasoreactivity and in intensive care therapy of manifest right heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19663611     DOI: 10.1517/14656560903164228

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  3 in total

Review 1.  Prostanoids and their analogues for the treatment of pulmonary hypertension in neonates.

Authors:  Binoy Shivanna; Sharada Gowda; Stephen E Welty; Keith J Barrington; Mohan Pammi
Journal:  Cochrane Database Syst Rev       Date:  2019-10-01

Review 2.  Pharmacotherapy for pulmonary hypertension.

Authors:  Robin H Steinhorn
Journal:  Pediatr Clin North Am       Date:  2012-08-26       Impact factor: 3.278

Review 3.  Pulmonary hypertension in bronchopulmonary dysplasia.

Authors:  Sara K Berkelhamer; Karen K Mestan; Robin H Steinhorn
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.